Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.
[[thumbnail_alt_text]]
Clinical pharmacy specialists review data on new and pipeline BTK inhibitors (acalabrutinib and LOXO-305, respectively) in the frontline setting for CLL.
 
[[thumbnail_alt_text]]
Of 192 study participants who received Breyanzi, 73% achieved a response, including 54% who had minimal or no detectable lymphoma remaining following treatment and 19% who achieved a partial response.
 
[[thumbnail_alt_text]]
The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.
[[thumbnail_alt_text]]
Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about what CAEL-101 is, how it works, and how it is used to treat patients with amyloid light chain amyloidosis.
[[thumbnail_alt_text]]
Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.
[[thumbnail_alt_text]]
Since its introduction to the US market in 2003, questions have risen as to the safety, long-term consequences, and risk of cardiovascular detriments that e-cigarettes pose to users.
[[thumbnail_alt_text]]
Considerations regarding the current roles of rituximab and splenectomy as treatment options in immune thrombocytopenia as additional therapies emerge.
[[thumbnail_alt_text]]
Rather than having an intrinsically lower risk of severe COVID-19, the patients in the study may have adhered more strictly to social distancing guidelines compared to the general population.
 
[[thumbnail_alt_text]]
Patients with AML that has gone into remission following initial chemotherapy were found to remain in remission longer and have improved OS if they took a pill form of azacitidine as a maintenance treatment.
[[thumbnail_alt_text]]
The study authors found marked improvements in rates of hazardous prescribing over the 12-month study period and the success of the intervention was sustained at the end.
 
[[thumbnail_alt_text]]
Daniel Wojenski, PharmD, discusses use of BTK inhibitors, primarily ibrutinib, as monotherapy vs in combination therapies as frontline treatment for CLL.